Senators reach deal on PBM and generics reform; Morphic study shows promise for ulcerative colitis

Taking stock of the drug industry, from the lab to the medicine chest

April 25, 2023 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Chip Somodevilla/Getty Images STAT+ | Sens. Bernie Sanders, Bill Cassidy reach deal on PBM, generic reform Sens. Bernie Sanders and Bill Cassidy laid out a bipartisan proposal to increase access to generic drugs and increase PBM transparency. By Rachel Cohrs STAT+ | Morphic study shows promise — and blockbuster potential — for a pill to treat ulcerative colitis The company said its medicine induced complete remissions in 26% of patients with ulcerative colitis — achieving the goal of its study. By Adam Feuerstein STAT+ | FDA approves new treatment from Biogen for rare form of ALS The medicine, Qalsody, is intended to treat people with ALS caused by inherited mutations in a gene that is called SOD1. By Adam Feuerstein Adobe With little FDA oversight, melatonin supplements vary widely in actual dosage, study finds A study found melatonin gummies that were three times more powerful than advertised, raising questions about the FDA's oversight. By Nicholas Florko

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser